Icon (ICLR) Competitors

Icon (NASDAQ:ICLR) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Which has more risk & volatility, ICLR or MEDP?

Icon has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Is ICLR or MEDP more profitable?

Medpace has a net margin of 18.74% compared to Icon's net margin of 9.82%. Medpace's return on equity of 67.66% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	9.82%	10.95%	6.23%
Medpace	18.74%	67.66%	21.86%

Do insiders & institutionals believe in ICLR or MEDP?

95.6% of Icon shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media favor ICLR or MEDP?

In the previous week, Medpace had 8 more articles in the media than Icon. MarketBeat recorded 12 mentions for Medpace and 4 mentions for Icon. Medpace's average media sentiment score of 1.56 beat Icon's score of 0.87 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts rate ICLR or MEDP?

Icon presently has a consensus target price of $219.54, indicating a potential upside of 24.53%. Medpace has a consensus target price of $406.60, indicating a potential downside of 13.12%. Given Icon's stronger consensus rating and higher probable upside, research analysts clearly believe Icon is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81
Medpace	3 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

Which has preferable earnings & valuation, ICLR or MEDP?

Icon has higher revenue and earnings than Medpace. Icon is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.09B	1.76	$791.47M	$9.72	18.14
Medpace	$2.11B	6.23	$404.39M	$13.45	34.80

Summary

Medpace beats Icon on 9 of the 17 factors compared between the two stocks.